Presentations include complete Phase III results from the SAkuraStar study investigating satralizumab for the treatment of neuromyelitis
optica spectrum disorder (NMOSD), and new multiple sclerosis (MS) research, which provides insights into disease progression, including data from OCREVUS[R] (ocrelizumab) trials that advance understanding of neurofilament light chain (NfL) levels as a potential biomarker for predicting disability outcomes.
Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis
optica spectrum disorder.
As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis
optica spectrum disorder (NMOSD).
In the US, Soliris is also approved for the treatment of generalised MG in adult patients who are anti-AchR antibody positive and for the treatment of neuromyelitis
optica spectrum disorder (NMOSD) in adult patients who are anti-AQP4 antibody positive, in the EU as the first and only treatment of refractory gMG in adults who are anti-AchR antibody positive, and in Japan for the treatment of patients with gMG who are anti-AChR antibody positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy or plasmapheresis.
TM has a number of different causes including multiple sclerosis (MS), neuromyelitis
optica, and in association with connective tissue diseases, such as systemic lupus erythematosus and Sjogren's syndrome.
optica: a positive appraisal of seronegative cases.
Benjamin Greenberg, who leads the Conquer programs at UT Southwestern, including the Transverse Myelitis and Neuromyelitis
Optica Program and the Pediatric Conquer Program at Children's Medical Center Dallas.
Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis
optica: a critical review of the literature.
Brain MRI showed abnormal signals along the bottom of the fourth ventricle which was typically seen in neuromyelitis
optica (NMO) and in the cerebellum.
OKLAHOMA CITY Oklahoma Medical Research Foundation scientist Bob Axtell, Ph.D., has received a four-year grant from the National Institutes of Health to study a rare autoimmune disease called neuromyelitis
optica, or NMO.
Inebilzumab is being evaluated for the treatment of neuromyelitis
optica, a rare condition affecting the optic nerve and spinal cord and is in Phase II study.
It has been found that cetirizine - common allergy medication - is safe, well-tolerated, and may reduce relapses in patients with neuromyelitis